Veterinary
Dechra Pharmaceuticals to acquire Invetx
BofA Securities, Inc. is acting as exclusive financial advisor to Invetx and Latham and Watkins LLP is acting as legal advisor
![](https://www.petgazette.biz/wp-content/uploads/2021/12/ayla-verschueren-nWKMtmbpxQs-unsplash-780x470.jpg)
UK-based provider of veterinary pharmaceuticals Dechra has announced its plans to acquire Invetx, a Boston, MA-based company which specialises in protein-based therapeutics for animal health, for up to $520m (£402.76m).
You'll need to
subscribe to unlock this content. Already subscribed? Login?